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To the Editor: In his 1909 book Handcuff Secrets, Harry 
Houdini lifted the shroud of secrecy surrounding his perfor-
mances and revealed that his mystifying capacity to escape 
shackles and chains was based in painstaking effort and 
compromise. Shaking off straightjackets for example required 
dislocating  his  shoulders,  performance  after  performance, 
year after year. In the current issue of Molecular Therapy 
Nucleic Acids, Berkhout and Das argue that our recent find-
ings of indirect HIV escape from RNA interference (RNAi)1 
have  been  misinterpreted  as  a “Houdini  action”  (citation). 
However, the “escape act” that we observed is not an illusion 
but a painful additional example of HIV’s recurring ability to 
evade antiviral therapies.
In our recent work,1 we propagated HIV in vitro in the pres-
ence or absence of antiviral RNAi for 32 days. Extensive 
sequencing of virus that escaped RNAi, as well as control 
virus propagated in parallel cultures for the same period of 
time in the absence of RNAi, enabled distinction between 
mutations  due  to  RNAi-mediated  selective  pressure  ver-
sus those arising from drift or general selection for replica-
tion. Subsequent analysis of over 400 individual sequences 
revealed  a  statistically  significant  increase  in  nucleotide 
diversity in the U3 region of the long terminal repeat (LTR) 
for virus exposed to RNAi. Armed with this in-depth statistical 
analysis, we then introduced individual, mutant U3 regions 
back into the original parent HIV strain and clonally tested 
the roles of these specific LTR mutations on viral replication 
in the presence or absence of antiviral RNAi. Four such vari-
ants showed significantly enhanced replication compared to 
the wild-type virus in RNAi-protected cells. The RNAi-resis-
tant variants also exhibited enhanced transcriptional activity, 
and their replicative advantage in RNAi-protected cells was 
reduced by addition of a RNAi-enhancing small molecule. In 
concert with our prior investigation,2 these findings support 
the hypothesis that HIV can evolve as a stronger promoter 
to overwhelm the RNAi pathway with a large number of tran-
scripts. Unfortunately, this indirect escape also resulted in 
cross-resistance to combinatorial RNAi targeting two distinct 
and spatially distant sites in the HIV genome, thus complicat-
ing antiviral RNAi design.
In the general spirit of open scientific exchange, we appre-
ciate Berkhout and Das’ discussion, and we take this oppor-
tunity to discuss a number of questions they raise. One claim 
is that the mutants found to be indirectly resistant to RNAi 
are  not  truly  resistant.  As  shown  in  Supplementary  Fig-
ure S3, however, the four mutant viruses replicate to maxi-
mum titers of 104–105 IU/ml over 10 days in RNAi-protected 
cells, whereas the wild-type parental strain maximally rep-
licates to only 102–103 IU/ml over the same period. As one 
example, mutant LK-7 replicates to a maximum titer of 8 × 
104, 105, and 2 × 103 IU/ml in the presence of Ldr3, TatB2, or 
a combination of both short hairpin RNAs (shRNAs), respec-
tively, whereas the wild-type strain replicates to a maximum 
of 103, 4 × 103 or 102 IU/ml under identical conditions. In their 
prior work, Berkhout and Das have stated that a number 
of their variants exhibiting a tenfold to 100-fold increase in 
replicative titer compared to parental virus within 10 days of 
culture in RNAi-expressing cells are resistant to the RNAi.3 
Following  the  same  standard,  we  conclude  that  our  vari-
ants are likewise RNAi resistant. In addition, the mutants in 
RNAi-  protected cells do not replicate as rapidly as wild-type 
virus in unprotected cells, which is to be expected since the 
mutants still contain the RNAi targets, and which is consis-
tent with our model of indirect resistance. They key point 
is that by any metric (e.g., titers at any time point over the 
10-day time course, overall burst size, replication rate) the 
U3 mutants replicate to a much greater extent than the wild-
type strain on RNAi-protected cells. Furthermore, over time, 
and with additional opportunity for evolutionary adaptation 
by transcriptional fine-tuning, one could anticipate that these 
differences would become even more pronounced.
As another concern, Berkhout and Das state that mutants 
that  exhibit  resistance  to  only  one  small  interfering  RNA 
(siRNA) are in fact demonstrating specific resistance to the 
TatB2 siRNA; however, this is also a misinterpretation of our 
model. Mutants TC-19 and SCK-1, which exhibit resistance 
to only TatB2, are not necessarily specifically resistant to 
TatB2. It is likely that they do not exhibit resistance to Ldr3 
or  the  combination  because  the  transcriptional  activity  of 
these mutants is not sufficiently high to overwhelm the RNAi 
pathway primed with Ldr3, which was much more effective 
than TatB2 at suppressing HIV in our long-term study (see 
Figure 2a1). Mutant LK-7, the mutant with the highest tran-
scriptional activity, exhibited resistance to TatB2, Ldr3, and 
the combination. This result is consistent with our model of 
indirect cross-resistance, and suggests that a certain tran-
scriptional threshold must be exceeded to generate cross-
resistance to highly effective siRNAs and combinations.
Berkhout and Das also imply that the eight variants with 
mutations in the U3 region that did not demonstrate indirect 
resistance  are  inconsistent  with  our  model,  because  they 
contain mutations in U3 that are “similar” to those in the RNAi-
resistant mutants. However, we would not expect all muta-
tions in the U3 region to result in resistance because some 
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are known to be neutral. We cited important work published 
by Wang and colleagues who found that some specific muta-
tions we observed (e.g., from the HIV nuclear factor (NF)-κB 
consensus  sequence  GGGACTTTCC  to  GAGACTTTCC) 
significantly reduced affinity for the p50 homodimer,4 which 
could in turn enhance HIV transcription by decreasing bind-
ing of the transcriptionally repressive p50 homodimer to the 
NF-κB sites.5 This same binding affinity study4 elegantly dem-
onstrated that not all mutations are “created equal,” and other 
mutations in the NF-κB consensus sequence (for example, 
GGGGCTTTCC) do not alter p50 homodimer binding. Thus, 
some U3 mutations may have a significant impact on pro-
moter activity and RNAi resistance, and others may not.
Berkhout  and  Das’  statement  that  our  transcriptional 
activity assay is not valid is also based on misinterpreta-
tion of the methods. We measured transcriptional elonga-
tion using a quantitative PCR method first developed by the 
esteemed Eric Verdin, Warner Greene, and colleagues.5–7 
The method is versatile and has been adopted by other 
groups,8,9 because it allows one to gather quantitative infor-
mation on both initiated and fully elongated transcripts from 
actual integrated virus (compared to transient transfection 
of micrograms of a reporter plasmid, which can exhibit arti-
facts). For this assay, we infected cells with mutant or wild-
type stocks that were quantified by measuring infectious 
titers, which we find to be more biologically relevant than 
p24 concentrations. By infecting with the same number of 
infectious units per cell (i.e., equal multiplicity of infection, 
or MOI), we removed any variation that could otherwise be 
introduced  into  the  steps  of  genome  packaging,  reverse 
transcription, and integration. Furthermore, we quantified 
viral message levels at steady-state, 3 days postinfection, 
which  are  in  turn  directly  related  to  transcription  of  the 
nearly identical viral mRNA sequences.
Berkhout and Das also claim that transcriptional enhance-
ment was only seen for 50% of mutants, and thus is not consis-
tent with our model. Although we did not see an enhancement 
of transcription for all resistant variants, we do not claim that 
this mechanism is mutually exclusive of all other mechanisms of 
resistance, and others may be at play. Again, we simply wish to 
draw attention to alternative mechanisms of resistance. More-
over, Berkhout and Das do not offer a satisfying explanation for 
why enhancement of the RNAi pathway using enoxacin results 
in  synergistic  inhibition  of  RNAi-resistant  mutants  if  indirect 
resistance is not a factor.
As another concern, Berkhout and Das believe that the 
Sp1 duplications we previously observed “reflect a general 
improvement of the attenuated HIV-1 strain used in these 
experiments  rather  than  a  general  RNAi  escape  mecha-
nism.” This interpretation is inconsistent with the data and 
controls we conducted at the time of publication.2 First, at 
the same time as enabling transcriptional upregulation and 
overwhelming  RNAi  in  the  protected  cells,  the  Sp1  dupli-
cations consistently reduce viral replication in unprotected 
cells. That is, HIV “dislocates its shoulder” and reduces fit-
ness in unprotected cells in order to overcome RNAi in the 
protected cells. This finding, along with the fact that we never 
observed such Sp1 duplications in HIV that was extensively 
propagated in parallel cultures without the RNAi, indicates 
that our observed mutations did not help, but in fact harmed, 
the wild-type HIV strain under the baseline culture conditions 
used. Moreover, we carefully cloned the Sp1 mutations into 
a full-length strain and rigorously quantified replication of the 
wild-type and mutant strains in the presence and absence of 
antiviral RNAi to demonstrate that the Sp1 duplications are 
not merely a reflection of general improvement of an attenu-
ated strain, but bona fide indirect resistance to RNAi.2
Berkhout and Das also claim that in our original publica-
tion direct escape routes were not observed due to medio-
cre RNAi knockdown in which we targeted the TAR hairpin 
with RNAi.2 They cite a knockdown of 20%, which was first 
characterized by a reporter assay knockdown of green flu-
orescent protein (GFP) (in which the target construct also 
overexpressed Tat, making potent knockdown highly chal-
lenging and thus underestimating the true antiviral potency 
of the anti-TAR siRNA). More importantly, inhibition of infec-
tious HIV titer was nearly complete.2 Furthermore, given the 
highly  conserved  and  functionally  important  nature  of  the 
structured TAR hairpin,2 where mutations are strongly disfa-
vored, we believe that we observed indirect escape precisely 
because  this  targeted  region  was  not  amenable  to  direct 
escape. At any rate, our more recent work1 utilized potent, 
previously published shRNAs,10 and we again observed indi-
rect mechanisms of HIV escape.
There  was  also  discussion  about  the “dangerous”  burst 
size metric, which we simply defined as the sum of all virus 
produced over the 10 days of culture, i.e., the integral under 
the  replication  time  course  curve. This  metric  is  generally 
useful for comparing the replication of many mutants under 
many conditions. For rapidly replicating virus, it is possible 
that bursts sizes can be reduced relative to wild-type virus in 
the absence of RNAi because of excessive cell death early 
in the time course. We addressed this nuance at the time of 
publication and referred to complete replication time courses 
(Supplementary Figure S3) to clarify the subtlety. Regard-
less, as mentioned above, titers for RNAi-resistant mutants 
were higher than those of the wild-type virus in the RNAi-pro-
tected cells throughout the 10-day time course, indicating that 
the burst size metric accurately captures virus dynamics.
We share with Berkhout and Das a firm belief that RNAi 
must continue to play a central role in the search for new 
classes of antiviral therapies, but, as with highly active anti-
retroviral therapy, combinatorial therapies are very effective 
but may well not be escape-proof. We also emphasize that 
the infectious disease literature is brimming with examples 
of surprising drug evasion mechanisms. As the field further 
advances into the genomic age, researchers are encouraged 
to sequence entire genomes, beyond the intended target, and 
investigate all paths and mechanisms for viral escape. We 
must choose to contend with painful realities, and set aside 
distracting illusions.
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